These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

125 related items for PubMed ID: 15752558

  • 1. From toxin to adjuvant: basic mechanisms for the control of mucosal IgA immunity and tolerance.
    Lycke N.
    Immunol Lett; 2005 Mar 15; 97(2):193-8. PubMed ID: 15752558
    [Abstract] [Full Text] [Related]

  • 2. ADP-ribosylating bacterial enzymes for the targeted control of mucosal tolerance and immunity.
    Lycke N.
    Ann N Y Acad Sci; 2004 Dec 15; 1029():193-208. PubMed ID: 15681758
    [Abstract] [Full Text] [Related]

  • 3. Targeted vaccine adjuvants based on modified cholera toxin.
    Lycke N.
    Curr Mol Med; 2005 Sep 15; 5(6):591-7. PubMed ID: 16178769
    [Abstract] [Full Text] [Related]

  • 4. Adjuvanticity of the cholera toxin A1-based gene fusion protein, CTA1-DD, is critically dependent on the ADP-ribosyltransferase and Ig-binding activity.
    Agren LC, Ekman L, Löwenadler B, Nedrud JG, Lycke NY.
    J Immunol; 1999 Feb 15; 162(4):2432-40. PubMed ID: 9973526
    [Abstract] [Full Text] [Related]

  • 5. The B-cell targeted CTA1-DD vaccine adjuvant is highly effective at enhancing antibody as well as CTL responses.
    Lycke N.
    Curr Opin Mol Ther; 2001 Feb 15; 3(1):37-44. PubMed ID: 11249730
    [Abstract] [Full Text] [Related]

  • 6. ADP-ribosylation controls the outcome of tolerance or enhanced priming following mucosal immunization.
    Hasselberg A, Ekman L, Yrlid LF, Schön K, Lycke NY.
    J Immunol; 2010 Mar 15; 184(6):2776-84. PubMed ID: 20142362
    [Abstract] [Full Text] [Related]

  • 7. Genetically engineered nontoxic vaccine adjuvant that combines B cell targeting with immunomodulation by cholera toxin A1 subunit.
    Agren LC, Ekman L, Löwenadler B, Lycke NY.
    J Immunol; 1997 Apr 15; 158(8):3936-46. PubMed ID: 9103464
    [Abstract] [Full Text] [Related]

  • 8. Mucosal adjuvants and anti-infection and anti-immunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG DNA.
    Holmgren J, Adamsson J, Anjuère F, Clemens J, Czerkinsky C, Eriksson K, Flach CF, George-Chandy A, Harandi AM, Lebens M, Lehner T, Lindblad M, Nygren E, Raghavan S, Sanchez J, Stanford M, Sun JB, Svennerholm AM, Tengvall S.
    Immunol Lett; 2005 Mar 15; 97(2):181-8. PubMed ID: 15752556
    [Abstract] [Full Text] [Related]

  • 9. Mucosally induced immunological tolerance, regulatory T cells and the adjuvant effect by cholera toxin B subunit.
    Sun JB, Czerkinsky C, Holmgren J.
    Scand J Immunol; 2010 Jan 15; 71(1):1-11. PubMed ID: 20017804
    [Abstract] [Full Text] [Related]

  • 10. Mast cells contribute to the mucosal adjuvant effect of CTA1-DD after IgG-complex formation.
    Fang Y, Larsson L, Mattsson J, Lycke N, Xiang Z.
    J Immunol; 2010 Sep 01; 185(5):2935-41. PubMed ID: 20675596
    [Abstract] [Full Text] [Related]

  • 11. The combined CTA1-DD/ISCOM adjuvant vector promotes priming of mucosal and systemic immunity to incorporated antigens by specific targeting of B cells.
    Helgeby A, Robson NC, Donachie AM, Beackock-Sharp H, Lövgren K, Schön K, Mowat A, Lycke NY.
    J Immunol; 2006 Mar 15; 176(6):3697-706. PubMed ID: 16517738
    [Abstract] [Full Text] [Related]

  • 12. A novel concept in mucosal adjuvanticity: the CTA1-DD adjuvant is a B cell-targeted fusion protein that incorporates the enzymatically active cholera toxin A1 subunit.
    Agren L, Löwenadler B, Lycke N.
    Immunol Cell Biol; 1998 Jun 15; 76(3):280-7. PubMed ID: 9682972
    [Abstract] [Full Text] [Related]

  • 13. Cholera toxin and cholera toxin B subunit induce IgA switching through the action of TGF-beta 1.
    Kim PH, Eckmann L, Lee WJ, Han W, Kagnoff MF.
    J Immunol; 1998 Feb 01; 160(3):1198-203. PubMed ID: 9570534
    [Abstract] [Full Text] [Related]

  • 14. The M cell-targeting ligand promotes antigen delivery and induces antigen-specific immune responses in mucosal vaccination.
    Kim SH, Seo KW, Kim J, Lee KY, Jang YS.
    J Immunol; 2010 Nov 15; 185(10):5787-95. PubMed ID: 20952686
    [Abstract] [Full Text] [Related]

  • 15. Splenic marginal zone dendritic cells mediate the cholera toxin adjuvant effect: dependence on the ADP-ribosyltransferase activity of the holotoxin.
    Grdic D, Ekman L, Schön K, Lindgren K, Mattsson J, Magnusson KE, Ricciardi-Castagnoli P, Lycke N.
    J Immunol; 2005 Oct 15; 175(8):5192-202. PubMed ID: 16210624
    [Abstract] [Full Text] [Related]

  • 16. Neonatal sublingual vaccination with Salmonella proteins and adjuvant cholera toxin or CpG oligodeoxynucleotides induces mucosal and systemic immunity in mice.
    Huang CF, Wang CC, Wu TC, Wu KG, Lee CC, Peng HJ.
    J Pediatr Gastroenterol Nutr; 2008 Mar 15; 46(3):262-71. PubMed ID: 18376242
    [Abstract] [Full Text] [Related]

  • 17. Adjuvants modulating mucosal immune responses or directing systemic responses towards the mucosa.
    Cox E, Verdonck F, Vanrompay D, Goddeeris B.
    Vet Res; 2006 Mar 15; 37(3):511-39. PubMed ID: 16611561
    [Abstract] [Full Text] [Related]

  • 18. Complement activation and complement receptors on follicular dendritic cells are critical for the function of a targeted adjuvant.
    Mattsson J, Yrlid U, Stensson A, Schön K, Karlsson MC, Ravetch JV, Lycke NY.
    J Immunol; 2011 Oct 01; 187(7):3641-52. PubMed ID: 21880985
    [Abstract] [Full Text] [Related]

  • 19. Oral tolerance induction by mucosal administration of cholera toxin B-coupled antigen involves T-cell proliferation in vivo and is not affected by depletion of CD25+ T cells.
    George Chandy A, Hultkrantz S, Raghavan S, Czerkinsky C, Lebens M, Telemo E, Holmgren J.
    Immunology; 2006 Jul 01; 118(3):311-20. PubMed ID: 16827892
    [Abstract] [Full Text] [Related]

  • 20. New generation of mucosal adjuvants for the induction of protective immunity.
    Yuki Y, Kiyono H.
    Rev Med Virol; 2003 Jul 01; 13(5):293-310. PubMed ID: 12931340
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.